Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Our results highlight the need to evaluate the action of glucocorticoid on cancer progression in melanoma, thyroid and colon carcinoma in which B-RAF-V600E is a frequent oncogene, and cancers in which evasion from senescence has been shown. 31371485

2019

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report. 31185985

2019

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. 29127628

2019

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE A colon cancer cell line with RNF43-G659Vfs*41 and BRAF-V600E mutations was sensitive to activation of Wnt/β-catenin signaling. 31811196

2019

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear. 30872078

2019

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. 29127628

2019

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE A colon cancer cell line with RNF43-G659Vfs*41 and BRAF-V600E mutations was sensitive to activation of Wnt/β-catenin signaling. 31811196

2019

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Vemurafenib is a B-Raf V600E inhibitor that exerts significant inhibitory effects in melanoma but not in colon cancer, and the mechanism of vemurafenib resistance remains unclear. 30872078

2019

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Our results highlight the need to evaluate the action of glucocorticoid on cancer progression in melanoma, thyroid and colon carcinoma in which B-RAF-V600E is a frequent oncogene, and cancers in which evasion from senescence has been shown. 31371485

2019

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report. 31185985

2019

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Colon carcinoma BRAF V600E HT29 cells exhibited poor response to radiation compared to BRAF wild-type COLO320 and HCT116 cells. 29663854

2018

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE However, the cluster drawn by the two mutations of V600E and E542K showed that all samples with those mutations belonged to the right-sided colon cancer group. 29556349

2018

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Colon carcinoma BRAF V600E HT29 cells exhibited poor response to radiation compared to BRAF wild-type COLO320 and HCT116 cells. 29663854

2018

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE However, the cluster drawn by the two mutations of V600E and E542K showed that all samples with those mutations belonged to the right-sided colon cancer group. 29556349

2018

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE In 212 RAS wild-type patients, V600E mutation was higher in older patients (9.5% vs. 2.2%, p=0.017), women (9.2% vs. 2.2%, p=0.021) and right-sided CRCs (10.5% vs. 3.4%, p=0.06). dMMR was detected in 7.75% of all stages of CRCs, with the highest dMMR rate of 40% in stage II right-sided colon cancer. 28416767

2017

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE In 212 RAS wild-type patients, V600E mutation was higher in older patients (9.5% vs. 2.2%, p=0.017), women (9.2% vs. 2.2%, p=0.021) and right-sided CRCs (10.5% vs. 3.4%, p=0.06). dMMR was detected in 7.75% of all stages of CRCs, with the highest dMMR rate of 40% in stage II right-sided colon cancer. 28416767

2017

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE The mutational status of KRAS and BRAF(V600E) oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses. 26872400

2016

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE The mutational status of KRAS and BRAF(V600E) oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses. 26872400

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE We reproducibly associate higher expression of the ligand-receptor axis of TFF2 and CXCR4 with BRAF V600E-mutant colon cancer (P = 3.0 × 10(-3) and 0.077, respectively for TCGA; P = 3.0 × 10(-8) and 5.1 × 10(-7) for CIT). 25899003

2015

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF (V600E) and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). 26160882

2015

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE In conclusion, our findings suggest that targeting ErbB-3 receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer. 26160848

2015

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE The BRAF V600E mutation is reportedly associated with inferior survival among colon cancer patients. 25636897

2015

dbSNP: rs1217691063
rs1217691063
0.100 GeneticVariation BEFREE In summary, this meta-analysis suggests that MTHFR C677T polymorphism is associated with increased breast cancer, gastric cancer, and hepatocellular cancer risk in Asians, is associated with increased gastric cancer, multiple myeloma, and NHL risk in Caucasians, is associated with decreased AALL risk in Caucasians, is associated with decreased CALL risk in Asians, is associated with increased breast cancer risk in Asians, is associated with decreased colon cancer risk, and is associated with decreased colorectal cancer risk in male population. 26081619

2015

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE The BRAF V600E mutation is reportedly associated with inferior survival among colon cancer patients. 25636897

2015

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE BRAF (V600E) and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). 26160882

2015